Janssen opens new biomanufacturing building in Ireland

8 Oct 2019

Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

Janssen Sciences Ireland UC, part of the Johnson & Johnson family of companies, has officially opened its new manufacturing building in Ringaskiddy, Co. Cork. The company has operated a biopharmaceutical supply chain facility on its 40-hectare site in Ringaskiddy since 2005.

Janssen opens new biomanufacturing building in Ireland

The expansion of the biomanufacturing site increases the company’s production capacity by an additional 19,100 m2 and creates 200 new full-time jobs. Approximately 450 people were employed on-site during the 2-year construction project.

The official opening ceremony for the facility was attended by Simon Coveney TD, An Tánaiste and Minister for Foreign Affairs & Trade, Kathy Wengel, Executive Vice-President and Chief Global Supply Chain Officer, Johnson & Johnson and Martin Shanahan, CEO, IDA Ireland.

Speaking at the event, An Tánaiste Simon Coveney TD, said: “I’m delighted to attend the official opening of Janssen’s new manufacturing building, which marks the company’s ongoing commitment to Ireland and patients around the world. The life sciences industry makes a hugely significant contribution to the national economy in terms of jobs and exports. In 2018 alone, 33% of Ireland’s total exports were pharmaceutical and medical products, with Johnson & Johnson featuring as one of our single largest exporters. Finally, I would like to extend my congratulations to the team here in completing this exciting expansion and I wish them continued success in the future.”

Kathy Wengel, Executive Vice President and Chief Global Supply Chain Officer, Johnson & Johnson said: “Our manufacturing facilities in Cork are at the cutting-edge of delivering healthcare solutions, which is an important part of our Credo commitment to provide the highest quality products to patients. Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions that advance how medicines are manufactured so that we can be at the forefront of treating, preventing, intercepting and curing some of the world’s most devastating and complex diseases.”

Martin Shanahan, CEO, IDA Ireland, said: “Johnson & Johnson is one of the largest life sciences and R&D investors in Ireland and is part of a thriving Biopharma sector in Cork. With a significant investment in expanding Janssen’s manufacturing capacity here in Ringaskiddy, the positive economic spin-off for the South-West region is considerable. On behalf of IDA Ireland, I would like to congratulate the Janssen team on successfully delivering a new, state-of-the-art manufacturing building in the heart of Cork’s life sciences hub.”

Read More

Related tags

Market News

Related news

CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
Catalent completes purchase of biologics fill-finish and oral solid dose facility

Catalent completes purchase of biologics fill-finish and oral solid dose facility

7 Jan 2020

Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.

Read more 
Boxing clever: Smart packs improving communication with patients

Boxing clever: Smart packs improving communication with patients

6 Jan 2020

Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.

Read more 
WuXi STA opens large-scale oligonucleotide manufacturing facility

WuXi STA opens large-scale oligonucleotide manufacturing facility

6 Jan 2020

Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
UCB to build new biotech manufacturing plant in Belgium

UCB to build new biotech manufacturing plant in Belgium

31 Dec 2019

Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

27 Dec 2019

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.

Read more